drugset / Trial / NCT00952575
Dose-finding Study of LFB-R593, A Monoclonal Anti-RhD Antibody, in Healthy RhD Negative Volunteers
RandomizedParallel-groupOpen-label
Summary
This phase II study is designed to demonstrate the ability of LFB-R593 to effectively eliminate exogenously-administered RhD-positive red blood cells from the circulation of an RhD-negative individual, thereby preventing RhD-alloimmunisation.
Timeline
- Start
- 2009-08
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LFB-R593 | Monoclonal antibody | — | — |
| Comparator | polyclonal anti-D immunoglobulin | Unknown | 300 ug | — |
Indications
No indication recorded.